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Discovery of anti-fungal compounds from the immunobiome of North American bat 
species threatened by fungal infection with Pseudogymnoascus destructans 
 




With the spread of bat White-nose Syndrome decimating regional bat populations, 
finding a safe antifungal agent able to combat the causative agent Pseudogymnoascus 
destructans is a necessity. Upsetting the already fragile microbial balance on the skin of 
bats with, or at risk of developing, White-nose Syndrome is ill-advised. To avoid this, 
microbes that already reside on the skin of bats and in their hibernacula have been screened 
for anti-fungal activity.  
Co-culturing cutaneous and environmental microbes against Pseudogymnoascus 
destructans and closely related species has yielded many potential candidates for antifungal 
bioactivity. The nature of the bioactivity was assessed by extracting the potentially 
antifungal compounds, screening them alone for bioactivity, and obtaining LC/MS profiles 
of all extracted compounds. 
While five prime candidates were screened for activity, it was found that four were 
only able to produce significant inhibition when cocultured, indicating that their bioactivity 
is a result of resource competition or induction of antifungal compounds under the stress of 
co-culture conditions. The final strain shows innate antifungal properties based on the 
treatment of the Pseudogymnoascus fungi with compounds produced by the pure isolate 
strain. It shows increased bioactivity against Pseudogymnoascus destructans, specifically. 
The extracted compounds have been found to be stable for at least four weeks in solution 
without degrading and were able to maintain bioactivity for 8 weeks. 
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1.1 Physiology and Anatomy of Chiropterans 
Chiropterans, or bats, are diverse and unique organisms; bats are the second largest 
order of class Mammalia and the only mammalian order capable of self-sustained flight.1 
A behavioural adaptation characteristic of bats in colder climates is hibernation. In the 
winter, bats will enter a low metabolic state known as torpor for bouts spanning from a few 
days to a month.1 In the state of torpor, bats will reduce their body temperature to match 
the ambient temperature of the hibernacula, as well as reducing their heart rate and 
breathing from 200-300 beats/min and 100-200 breaths/min, to 3-5 beats/min and 4-6 
breaths/min, respectively.1,2 To account for the extended period without food and water, 
bats will build up their fatty tissue before entering torpor to allow for them to be broken 
down by fatty acid oxidation. While in torpor, the bat’s metabolism drops to nearly 1% of 
their euthermic states, requiring some functions to be sacrificed—such as immune, 
circulatory, and pulmonary-respiratory functions.1 
Their patagium, or wing membrane, is possibly their most exceptional structural 
feature, both morphologically and functionally. The skin of the patagium is distinct from 
the skin of the rest of the body; it is highly folded and at least ten times thinner than the 
skin covering the rest of the body.3 Composed of two epidermal layers encasing a 
vascularized connective tissue core, the patagium acts as a surface for passive gas 
exchange, but also evaporative water loss.2,3  The sebaceous and apocrine glands on the 
wing provide a moisturising and waterproofing layer to the surface of the skin, but even 
still, up to 99% of the water loss in a hibernating bat occurs due to evaporative water 
loss.  This layer is also thought to interact with the skin microbiome of bats by providing 
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nutrients to beneficial microbes, while acting as a barrier against harmful ones.2 However, 
as evident by the recent outbreak of bat White-nose Syndrome in North America, this 
mechanism is not perfect. 
 
1.2 White-Nose Syndrome and Pseudogymnoascus destructans 
White-nose Syndrome (WNS) is a fungal infection that has decimated some North 
American bat populations. Since the first documented case in New York in 2006, WNS has 
spread to 33 states and 7 provinces (as of March 2019).4–6 Some species have been 
classified as regionally endangered or extinct with population decreases from 90-100% in 
some counties.4,5,7 WNS is characterized by the presence of a powdery white growth of 
fungus Pseudogymnoascus destructans (Pd) on the muzzle, ears and patagium of 
hibernating bats. 5,8,9 
This previously uncharacterized fungus was initially identified as a close relative to 
genera Geomyces and Pseudogymnoascus based on analyses of the internally transcribed 
spacer (ITS) region and small subunit ribosomal RNA gene sequences.5,7 In 2009, it was 
classified and named Geomyces destructans, but was later reclassified as 
Pseudogymnoascus destructans in 2013 based on its distinctive morphology and repeated 
gene sequence analysis.5,7,10 Initially, the presence of Pd was associated with WNS, but no 
strong evidence pointed towards the fungus as the causative agent of the disease. There was 
doubt, as the fungus was found in Europe with no associated disease and most fungal 
infections lead to immune system dysfunction—a feature not present in the pathogenesis 
of the WNS. However, in 2011, Pd was confirmed to be the causative agent of White-nose 
Syndrome by experimentally inoculating healthy Myotis lucifugus with pure cultures of Pd. 
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This inoculation successfully induced WNS in bats, and live Pd could be cultured from 
diseased bats, meeting the criteria of a primary pathogen.11 
  The fungal hyphae invade hair follicles, sebaceous 
glands, and apocrine glands. In the wings, the hyphae 
extend through the thin epidermis into the vascular and 
connective tissue. The colonization and invasion of the 
fungus prevents passive gas exchange across the wing 
membrane, causing an increase in blood CO2, resulting in 
acidemia and hyperkalemia.3,12 The interruption in passive 
respiration increases the rate of pulmonary respiration and 
low blood pH induces hyperventilation, which is both 
metabolically expensive and leads to increased pulmonary 
evaporative water loss. This leads to depletion of fat 
reserves, even before torpor patterns are disrupted.12 
Arousal is induced by dehydration and the acidemia, 
requiring the bat to reheat itself to euthermic temperatures, resume active pulmonary gas 
exchange, and forage for food and water. The arousal process further depletes fat stores 
prematurely, reducing the bats’ chances of surviving through the winter period.3,11–14 
      The sudden population devastation and rapid spread of WNS through North 
America raised a critical question: what caused the 2006 WNS outbreak? Two hypotheses 
remained prevalent throughout the search for the origin of the disease: the endemic 
pathogen hypothesis and the novel pathogen hypothesis.15 The endemic pathogen 
hypothesis states that Pd may have been a native fungus that, through genetic mutation, 
Figure 1. Disease cascade in 
bat White-nose Syndrome.10 
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developed characteristics causing it to be more pathogenic to bat populations. Whereas the 
novel pathogen hypothesis states that the fungus was an invasive species introduced to 
North America from a different geographical region.16 The endemic pathogen hypothesis 
was challenged by the lack of species closely related to Pd for the fungus to have evolved 
from.14 Furthermore, genotypic evidence suggest a clonal spread of Pd across the east coast 
to the Midwest, with only a single mating type, an unusual model for the natural 
development and spread of a native species.17,18 In contrast, it has been determined that Pd 
is widespread in Europe with two mating types present to participate in sexual 
recombination by a heterothallic mating system—whereby different sexual structures exist 
in different individuals.19–23 The most striking piece of evidence at the time, which altered 
the favoured hypothesis towards Pd being a novel pathogen in North America, was the lack 
of mass mortality in European hibernacula in the presence of the fungus. This evidence 
suggested a resistance to the fungus due to long exposure and coevolution of the Pd fungus 
and the bat species in the area.19,24 To confirm that differences in pathogenicity between the 
European and North American strains was not causing the differences in mortality, North 
American bats were inoculated with European isolates of the fungus. This resulted in 
symptoms and mortality characteristic of White-nose Syndrome, revealing that the 
European fungus was also sufficient to induce the disease.16 This not only provided 
evidence for the origin of the fungus, but also provided a model of study for Pd resistance 
in European bats, which could be applied to control spread and mortality in North American 
populations. Further evidence that pinpointed Europe as the specific site of origin was the 
presence of eight distinct haplotypes in Europe and only one present in North America 
(based on the presence of variation at eight loci); the most common haplotype in Europe 
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(Hap_1) is shared among all Pd isolates from Canada and the United States.25 In-depth 
phylogenetic analysis and molecular dating of Pd strains from North America, Europe and 
Asia show distinct populations in Europe (with the North American isolates nested in this 
population), China, and Mongolia. Among the European population (including the North 
American isolates) diverged in the last century and diverged from the Asian populations 
over 3000 years ago.26 This evidence confirms that, ancestrally, Pd originated in the 
Palaearctic region, and was only transferred to North America recently. 
 
1.3 Resistance to White-nose Syndrome 
To further understand the mechanism behind the European bat resistance, 
comprehensive investigation went into the immune function of unaffected and affected 
bats—both North American and European; these studies revealed surprising differences. It 
was determined that North American bat species mount an immune response despite 
immune downregulation in the torpid state.27–32 Resistance to a pathogen requires a 
coordinated and adapted immune response, whereby innate immune mechanisms are 
regulated and targeted for an effective and appropriate response. While North American 
bats show evidence of immune system regulation, the decreased survival may be due to the 
lack of specificity, efficiency, and targeting in the mounted response.  
In torpid bats, there is a characteristic lack of inflammation; however, upon arousal 
and return to a euthermic state, intense neutrophilic inflammation and emaciation of wing 
tissue is observed.30,32 This has been attributed to an immune reconstitution inflammatory 
response, whereby an immunosuppressed host is infected, then upon the return to an 
immunocompetent state a severe immune response is mounted to combat the now-
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established infection.30 However, there is evidence of increased white blood cell and 
cytokine activity in affected bats, even while torpid.27,31,32 Increased activation of 
cathelicidins, pro-inflammatory cytokines, and inflammatory response modulators reveal 
that an inflammatory response is being mounted but not effectively carried through.31,32 
One proposed issue is inappropriate targeting; the gene expression of these inflammation 
factors occur primarily in the lungs.31 Thus far, there is no evidence that Pd infects the 
lungs; this response may be a non-specific host response to unknown fungal invasion or it 
may successfully be preventing establishment of spores in the lung tissue. Regardless, this 
response does not prevent infection and spread on the surface of the wings, as it is observed 
that, despite cytokine and chemokines being appropriately expressed, there is no 
recruitment of immune cells to the infection sites.32   
Immune response comparison between affected and unaffected bats, as well as 
affected North American bats and European bats, reveal that antibody-mediated response 
cannot explain the resistance observed. Higher expression of anti-Pd antibodies was 
observed in affected North American bats than affected European bats, as well as decreased 
mass correlated with production of certain anti-Pd antibodies.28,29 However, it should be 
noted, that infected bats that continue to successfully emerge from hibernation in regions 
of North America where Pd has been present longest also had higher antibody levels than 
emerging bats in more recently infected regions, providing little clarity to the role of 
antibodies in WNS resistance.28 While evidence shows that classical host-immunity models 
may not be able to explain reduced severity of infection, there is evidence that micro-
ecological defenses might.29,33–39  
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1.4 Microecological Defenses: Immune-Relevant Microbe-Microbe Interactions 
 While therapeutic agents for microbial pathogens have historically focused on 
diversified antimicrobials, probiotics may be the key in fighting infection by providing new 
models for treatment, as well as new sources of naturally-derived antimicrobials.36 The 
scope of microorganisms that inhabit a host can be beneficial, benign, or pathogenic. These 
host-microbe relationships are 
not static; benign microbes of 
one host may become 
beneficial when introduced to 
another host, or they may 
become pathogenic. The host 
provides a habitat for the 
important microbe ecosystem 
that can provide protection from pathogen invasion. The term “immunobiome” describes 
the immune defenses provided by and shaped by microbes on the host organism, based on 
selective evolutionary and ecological pressure.36  
Microbial protection is due to metabolic secretions, which can nourish and 
contribute to host barriers, while others may act as antimicrobials to prevent competing 
microbes from colonizing and utilizing the same nutritional sources. This inhibition is a 
form of interference competition, whereby one organism uses a mechanism to prevent or 
slow other organisms from accessing shared resources. For this reason, microbes, 
especially those that inhabit hosts experiencing pathogen pressure (a strong competitor for 
resources), may be the key to new therapeutics for infection-based diseases, like WNS.  
Figure 2. Microbe-host interactions in the 
immunobiome. 
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 The first successful attempt at using microbe-derived treatments against Pd 
occurred in 2013, with bacterially produced volatile organic compounds (VOCs).37 In 2013, 
Cornelison et al. used fungistatic VOCs previously described to be produced by soil 
bacteria, including decanal, nonanal, and benzaldehyde; all six tested VOCs showed 
successful inhibition of conidial growth and mycelial extension.37 In 2014, Cornelison et 
al. continued studying volatile-based inhibition of Pd, this time investigating contact-
independent inhibition with bacteria Rhodococcus rhodochrous, a soil-associated bacteria 
known to delay fruit ripening.33 It was determined that induced R. rhodochrous caused 
complete inhibition of conidial growth in Pd when grown in a shared air-space. However, 
there are ecological concerns with the application of this treatment, as it would involve 
introduction of an endemic bacteria to an already fragile micro-ecosystem.  
The use of cave-adjacent soil and substrate microbes has been investigated to 
resolve this problem; if the inhibitory microbe is native to the cave environment, using 
treatments derived from it may be better tolerated. In 2015, Zhang et al. isolated a novel 
Trichoderma polysporum strain from a cave affected by WNS.35 Extracts from the strain 
not only showed marked inhibition of Pd, but also specific inhibition, as it did not inhibit 
the closely-related Pseudogymnoascus pannorum. The identity of the fungistatic 
compounds in the extract were not determined. In 2017, Micalizzi et al. of the M. Smith 
Lab at Carleton University (Ottawa, Canada) examined both contact-dependant and 
independent inhibition of Pd using strains sourced from various environmental substrates 
in cave areas.39 Analysis of VOCs from inhibitory strains identified four bioactive volatiles: 
2-methyl-1-propanol, 2-methyl-1-butanol, propanoic acid, and 1-pentanol. All four 
volatiles were tested directly against Pd, and complete inhibition occurred for all strains. 
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Contact-dependant strains were investigated in bioassays and spent-media tests, with 
several antagonist’s spent media showing inhibition against Pd, but not closely related P. 
pannorum or P. roseus. These provide strong candidates for isolating effective and specific 
anti-Pd natural products. However, identification of the compounds from the spent media 
was hindered because the compounds were highly water soluble and difficult to separate 
out without affecting the activity. 
In 2015, in an effort to find probiotic strains for direct treatment of WNS, Hoyt et 
al. isolated and investigated the anti-Pd activity of cutaneous bacteria directly off 
hibernating bats.34 Six Pseudomonas isolates were tested for contact-dependent activity by 
coculturing against Pd, with two isolates showing optimal inhibition at all concentrations. 
In 2016, the efficacy of one of these Pseudomonas isolates called Pf1 as an in vivo treatment 
was tested.38 It was determined that, when the bat was inoculated concurrently with Pf1 
and Pd disease severity was reduced; disease severity was measured based on wing lesions, 
surface fungi, Pd load, UV fluorescence, and torpor bout duration. While simultaneous 
inoculation reduced severity, it was found that pre-treatment with Pf1 actually increased 
severity.  
Together, these investigations strongly suggest the efficacy of microbially-derived 
treatments for White-nose Syndrome. While direct probiotic treatment and VOCs may be 
viable solutions to treating the WNS problem, further investigation into isolating coculture-
stimulated antimicrobial natural products may provide broader utility. Not only could they 
assist in treating other infectious diseases, but they could also lead to the development of 




The objectives of this study are to 1) create a microbial library derived from 
cutaneous samplings of WNS-resistant North American bat populations, 2) screen 
microbes for inhibitory activity against Pd and closely related species, and 3) identify the 
nature of any inhibition. By assessing bat populations that have shown some degree of 
resistance to the WNS epizootic, there is a greater expectation to find cutaneous microbial 
communities that are able to slow the growth of Pd. By co-culturing strains isolated from 
bats against the Pd fungus and other Pseudogymnoascus (Pga) species, it can be determined 
which strains are able to most effectively compete with the pathogen, visualized by 
inhibited growth. This inhibitory action will be assessed to determine whether it is specific 
to Pd or more generally anti-fungal, whether it is innate or induced, and whether it is based 
on resources competition or interference competition. Specificity will be assessed by 
comparing the degree of inhibitory activity in a pairwise assay against Pd with the 
inhibitory activity against three other Pseudogymnoascus species. To determine whether 
the inhibitory activity from pairwise testing is innate (produced by the pure strain without 
the threat of pathogen pressure) or induced (only produced when the strain senses nearby 
competitors), the metabolite profile of pure and pairwise grown strains will be compared 
to determine if novel molecules are produced as a result of co-culturing. Finally, to test 
whether competition is based on resources (growth inhibition based solely on the limited 
amount of space, nutrients, and carrying capacity of the environment) or interference 
(incendiary mechanisms to gain an advantage over competitors), Pseudogymnoascus fungi 
will be grown in the presence of metabolites extracted from pure isolated strains, without 
the cell component present to compete for resources.  
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2. Experimental 
The following work was performed in a Containment Level 2 laboratory and executed 
according to Canadian Biosafety Standards and Guidelines. Active strain work was 
completed in a biological safety cabinet and all materials used were disposed of in sealed 
containers for subsequent incineration. The standard operating procedures for autoclave 
use, biological safety cabinet use, decontamination, and waste disposal are outlined in the 
Saint Mary’s University Biosafety Manual. 
 
2.1 Assembling and Characterizing a Strain Library 
2.1.1 Sample Collection: 
Agar slants made from 10% Reasoner’s 2A 
(R2A) agar (HiMedia; 0.05g casein hydrolysate, 
0.05g dextrose, 0.05g starch, 0.05g yeast extract, 
0.03g dipotassium phosphate, 0.03g sodium 
pyruvate, 0.025g casein peptone, 0.025g meat 
peptone, 0.0024g magnesium sulfate, 15g agar 
powder, and 1000mL dH2O) with pre-wetted (sterile 
dH2O) sterile cotton swabs were sent to Dr. Paul Faure at the McMaster University Bat 
Lab. The Faure Group sampled Eptesicus fuscus (Big brown bats) by running one pre-
wetted swab over the muzzle five times, and another swab over the forearms five times 
each (Fig 3). The swabs were used to inoculate the agar slants and sealed in the slant 
container for transport.  
 
Figure 3. Sample collection from 
bat muzzle and forearm. 
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2.1.2 Strain Isolation: 
Upon receiving inoculated agar slants, each swab was used 
to inoculate a 10% yeast malt agar (YMA: HiMedia; 0.3g yeast 
extract, 0.3g malt extract, 1g dextrose, 20g agar powder, and 
1000mL dH2O) plate and a 10% R2A plate (Fig 4A). The plates 
were incubated at 19°C for four weeks to maximize strain 
development and diversity (Fig 4B). All morphologically distinct 
colonies were isolated by restreaking and allowed to grow for three 
weeks at 19°C (Fig 4C). Strains that were morphologically similar 
were cocultured pairwise for comparison and allowed to grow for 
two weeks at 19°C. Strains were tested on selective media 
(containing 100µg/mL ampicillin or 10µg/mL cycloheximide) in 
order to further separate strains and understand the identity of each 
unknown strain. Based on gross and microscopic examination of morphology, similarity in 
growth patterns, and behaviour in cold and selective media conditions, strains that were 
considered redundant were grouped to reduce the number of working strains. All isolated 
strains were transferred to 10% YMA and grouped again. Each morphologically distinct 
strain was isolated at least twice more to achieve pure strains, with some strains requiring 
up to five restreaks to separate closely-growing strains. The 39 resulting strains obtained 
from the Faure Lab were labelled with an F-strain number (e.g. F1) and six strains 
determined to be lab-introduced contaminants were labelled with a C-strain number (e.g. 
C1). Eleven pure microbial strains were obtained from Dr. Myron Smith’s lab at Carleton 



















University; these strains were labelled with an S-strain number (e.g. S1). The growth 
progression was tracked and described for two weeks.  
Concentrated strain-inoculated liquid media stocks were made by placing 1mL of 
100% yeast malt broth (YMB: HiMedia; 3g yeast extract, 3g malt extract, 10g dextrose, 
and 1000mL dH2O) on an agar plate containing a pure strain after at least one week of 
growth (Fig 5A). The surface of the plate was scraped with an inoculating loop to disturb 
and detach bacteria/fungi and disperse it in the broth (Fig 5B). The broth containing the 
microbes was transferred to a sterile cryovial (Fig 5C). Due to large fungal clusters 
preventing an even distribution in the broth, optical density could not be accurately 
determined.  These concentrated stocks were used for direct plating onto agar, for making 
working stocks in a 1:10 dilution in 100% YMB, and for making frozen stocks in a 1:1 
dilution in 50% glycerol (kept at -80°C for long term storage). 
 
2.1.3 Optimal Temperature Testing: 
All strains were inoculated (10µL of conc. strain-inoculated liquid media) on a 
single well in three sets of 24 well plates (well diameter: 1.5cm) containing 100% YMA 
(HiMedia; 3g yeast extract, 3g malt extract, 10g dextrose, 20g agar powder, and 1000mL). 
Each plate set was incubated at 12°C, RT (19-21°C), and 30°C. Growth was measured on 
Figure 5. Preparation of a concentrated stock  
A     B      C 
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Day 1 and Day 7. Temperature growth was scored from 0 to 3; a score of 3 signified strong 
growth (colony diameter > 1cm), a score of 2 signified moderate growth (0.5cm <  colony 
diameter  < 1cm), a score of 1 signified poor growth (colony diameter < 0.5cm but growth 
is still visible), and a score of 0 signified no growth (where no growth could be observed). 
Strains showing moderate to strong growth at 12°C were considered psychrotolerant. 
 
2.2 Preliminary Pairwise Testing 
The compiled strain library 
was tested pairwise against four 
species of Pseudogymnoascus fungi 
(Fig 6): Pseudogymnoascus bhatti 
(Pb), Pseudogymnoascus destructans 
(Pd), Geomyces (Pseudogymnoascus) 
pannorum (Pp), and 
Pseudogymnoascus roseus (Pr). 
Based on measured growth of the 
Pseudogymnoascus strains at 12°C 
and 19°C, Pd and Pr were used for 
pairwise testing at 12°C against 
psychrotolerant strains, while Pb and Pp were used for pairwise testing against the whole 
strain library (consisting of the F-strains, S-strains, and C-strains) at 19°C. Pairwise testing 




Figure 6. Morphology of Pseudogymnoascus 
species 
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 Pseudogymnoascus strains (P-strains) were 
inoculated on the plate (25µL of conc. liquid stock) and 
allowed to establish colonies (3 days for Pb/Pp, 5 days 
for Pd/Pr). This is due to the slow growing nature of 
each of the P-strains. Sample strains were inoculated 
(25µL of conc. liquid stock) opposite to the pre-
established colonies of a P-strain (Fig 7). Colony size, 
zone of inhibition, and P-strain growth were measured 
to determine the presence of inhibitory activity after 7 
days. The growth of the pairwise P-strains and pure P-strains were used to quantify and 
compare inhibitory effects. The mean colony size of the P-strain in the pairwise test 
(performed in triplicate) was determined and compared to the mean colony size of the pure 
P-strain (from 48 replicates) in the same growth conditions and timeframe by determining 
the difference between the values and dividing by pure growth to determine a percent 
inhibition. Percent inhibition was scored from 0 to 3; a score of 3 signified strong inhibition 
(75% < %inhibition ≤ 100%), a score of 2 signified moderate inhibition (50% < %inhibition 
≤ 75%), a score of 1 signified limited inhibition (25% < %inhibition ≤ 50%), and a score 
of 0 signified no inhibition (inhibition ≤ 25%). This process was used to determine which 
strains showed the most promising overall activity against the P-strains; only these strains 
were used for further analysis. 
 
Figure 7. Layout of a pairwise 
test plate. 
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2.3 Extraction and Fractionation of Metabolites 
To isolate metabolites from the media 
of pure and pairwise assays, strains were grown 
on a large scale on 100% YMA on 12-well 
plates (the number of plates used is dependent 
on purpose of extraction). The discs of spent 
media (4mL, 2cm in diameter) were removed 
from the plates and extracted three times with 
an equal volume of an 85:15 ethyl acetate-
methanol solution for 2 hours each (Fig 8). The solvent was gravity filtered to remove most 
particulate matter and transferred to a round bottom flask. The solvent was evaporated off 
(by rotary evaporation) and the solid was re-dissolved in ~5ml of MeOH and transferred to 
a pre-weighed vial through a 0.22micron filter to remove cells. The solvent was evaporated 
off and made up to 10mg/mL in HPLC-grade methanol. This was completed for the selected 
pure isolate strains (F1, F3, S2, S8, and S9), the P-strains, and the pairwise tests between 
each of the isolate strains and P-strains. 
The crude extract of each of the pure isolate strain (1mL of 10mg/mL in methanol) 
was fractionated using a gravity microcolumn with C18 silica (4cm height, approximately 
0.75g) and an acetonitrile/water gradient (10mL each of 0%, 10%, 20%, 50%, 80%, and 
100% acetonitrile in water). Each fraction was collected in scintillation vials and stored at 
room temperature for subsequent bioactivity testing and analysis. 
 
Figure 8. Extraction of media from a 12 
well plate. 
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2.4 Analysis of Extracts and Fractions 
To prepare for liquid chromatography (paired with mass spectrometry and a diode 
array detector; LC/MS/DAD), crude extracts were diluted to 5mg/mL in HPLC-grade 
methanol. Pure methanol and an extract of an uninoculated agar plate were used as controls. 
Crude extracts were analyzed using an Agilent 1100 series LC-MS equipped with an ion-
trap mass spectrometer (Agilent 110 Series LC/MSD Trap) and a diode array detector. The 
method utilized reverse phase liquid chromatography with a C18 column (Zorbax Eclipse 
XDB 80Å C18, 4.6 x 75mm, 3.5µm HPLC column). Fractions were eluted starting with 
20% acetonitrile (ACN) with 0.1% formic acid in deionized water (dH2O) with 0.1% formic 
acid for 25 min followed by 80% ACN (with 0.1% formic acid) in dH2O for 3min, then 
100% ACN (with 0.1% formic acid) for 5 min. A diode array detector was used to collect 
a full range chromatogram (190-400nm) and a chromatogram at wavelengths 212nm, 
225nm, 254nm, 275nm, and 350nm to detect the presence of compounds. Positive-mode 
electrospray ionization mass spectrometry was used to further detect and resolve 
compounds in the crude extract from 100m/z to 2200m/z. This was performed to obtain a 
broad overview of the compounds produced by the inhibitory strains, both while pure and 
paired with each Pseudogymnoascus strain, to determine if any novel metabolites are being 
induced by pairwise growth. The choice of column composition and mobile phase 
components were based on the Trichoderma polysporum metabolite separation performed 
by Zhang et al.35; the method was optimized for general separation of fungal metabolites 
with the help of Patricia Granados at the Saint Mary’s University Centre for Environmental 
Analysis and Remediation (CEAR) Lab, Halifax, NS. 
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2.5 Assessing Bioactivity of Extracted Metabolites 
2.5.1 Isolate-Supplemented Media Testing:  
In order to assess whether inhibition occurred by interference competition (use of 
inhibitory metabolites), as opposed to resource competition (inhibition by deprivation of 
resources), the growth of each P-strain was observed on media supplemented with the cell-
free extracts of the isolate strains. Upscaled growth of pure isolate strains occurred by 
inoculating five 12-well plates per strain—approximately 250mL of 100% YMA media. 
These plates underwent extraction and were made up to a stock concentration (10mg/mL) 
in methanol (Fig 9A). A subsequent batch of 100% YMA media was supplemented with 
the extract solution with a starting concentration of 100µg/mL extract in media (Fig 9B). 
P-strains were inoculated on the plates (Fig 9C) and degree of inhibition was based on 
coverage of the plate with P-strain fungus. A control plate was made for each P-strain by 
supplementing the media with 10mL of methanol per 1L of agar to ensure methanol was 




A  B   C 
Figure 9. Supplementation of media with an isolate strain extract. 
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After 10 days of growth, plate coverage was quantified with the ImageJ plugin 
ColonyArea, which measures the percent coverage based on coloration and color intensity 
of a photographed plate.40,41  The pathway used in the program is as followed: Plugins > 
ColonyArea > colony area > Input=1, row=1, column=1 > Plugins > ColonyArea > colony 
threshold > Plugin > ColonyArea> colony measure. Since the P-strain growth was 
considered the negative space due to its white colouration the Area Percent was subtracted 
from 100 to determine colony coverage. Percent coverage was scored from 0 to 3; a score 
of 3 signified full coverage (75% < % coverage ≤ 100%), a score of 2 signified moderate 
coverage (50% < % coverage ≤ 75%), a score of 1 signified reduced coverage (25% < % 
coverage ≤ 50%), and a score of 0 signified limited coverage (% coverage ≤ 25%). Reduced 
and limited coverage of the P-strain on isolate supplement media indicated partial to 
complete inhibition. 
Isolate strain S9 showed significant inhibitory activity in the initial supplemented 
media test (Fig 10A), so the media from each P-strain and control was extracted from the 
plate used for supplemented testing (Fig 10B). The extract was made up to 10mg/mL and 
used to re-supplement another round of media (Fig 10C), on which the appropriate P-strain 
was grown again (Fig 10D). The extraction and supplementation processes were completed 
once more for a total of three rounds (LC data was not collected after the third round). This 
process was used to assess the stability and continued bioactivity of the compounds 










2.5.2 Disc Diffusion Assay: 
Crude extracts and fractions were tested directly against the P-strains to determine 
which fraction(s) contain the bioactive molecule of interest for future compound isolation. 
Autoclaved circular discs (6mm diameter, Whatman Grade 1 Qualitative Filter Paper) were 
placed on 100% YMA media freshly inoculated with each P-strain (Fig 11A), then 10µL 
of crude extract or fraction was placed on the disc to allow it to absorb and diffuse outward 
into the media (Fig 11B; where *=crude, 1= 0% ACN, 2= 10% ACN, 3= 20% ACN, 4= 
50% ACN, 5= 80% ACN, and 6=100% ACN fractions). Plates were made up in triplicate 
and a control plate was made for each strain using 10µL of methanol for the crude and each 
respective acetonitrile in water solution to determine if the solvent had any effect on the P-
strain fungi. After 10 days of growth, the radii of the zone of inhibition around the discs 
were measured and averaged among the three trials (Fig 11C). The zone of inhibition was 
scored from 0 to 3; a score of 3 signified a distinct zone of inhibition (5mm < ZOI), a score 
Figure 10. Consecutive extraction and supplementation of S9 metabolites in P-strain 
media 
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of 2 signified a moderate zone of inhibition (2.5mm < ZOI ≤ 5mm), a score of 1 signified 
a visible zone of inhibition (0.5mm < ZOI ≤ 2.5mm), and a score of 0 signified no zone of 








3. Results and Discussion 
3.1 Assembling and Characterizing a Strain Library 
3.1.1 Sample Collection: 
The Faure Group at the McMaster Bat Lab sampled 40 healthy Eptesicus fuscus.  
Of the bats sampled, there were 29 adults (21 females, 8 males), which were captured near 
Molesworth, Ontario and 11 juveniles (4 females, 7 males), which were bred in captivity 
(Appendix A, Table A1). The muzzle samples from one of the adult females (P89) was not 
taken or was lost in transit, and the forearm swab showed no growth, thus it was excluded 
from remaining trials. Eleven pure strains were obtained from Dr. Myron Smith’s lab. Each 
of these strains was shown to have activity against at least one of the P-strains by the Smith 
lab39; however, they had limited success at extracting stable bioactive compounds from the 
media for analysis. 
Figure 11. Preparation and layout of a disc diffusion assay experiment. 






3.1.2 Strain Isolation: 
From the initial plates streaked, 179 strains were isolated (91 from YMA, 88 from 
R2A). Based on appearance and growth throughout three weeks, strains that appeared 
redundant were cocultured, and the strains confirmed to be redundant were grouped under 
a common strain number. This resulted in 127 strains (55 from YMA, 72 from R2A). Each 
strain was grown on selective media and this information, along with gross observation, 
was used to further group redundant strains. This resulted in 71 strains (39 From YMA, 32 
from R2A). After all strains were transferred to YMA, strain growth at various temperatures 
and on selective media was tested again; this resulted in 39 non-redundant strains called 
the F-strains. With the addition of the 11 Smith Lab strains, or the S-strains, and 6 
Contaminant Strains (strains found in later isolates and determined to be contaminants 
resulting from human error), C-strains, the isolate final library used for testing consisted of 
56 unique strains and 4 P-strains (Appendix A, Table A2). 
3.1.3 Optimal Temperature Testing: 
Of the 56 strains, 39 strains grew at 12°C, 56 strains grew at room temperature 
(approximately 19-21°C), and 54 strains grew at 30°C (Table 1; Growth Score >1 
considered sufficient growth). Of the P-Strains, Pd and Pr grow optimally at 12°C, Pb 






Table 1. Heatmap of temperature-based growth data for entire strain library 
Strain 
Temp. Growth Score* 
Strain 
Temp. Growth Score* 
Strain 
Temp. Growth Score* 
12°C 19°C 30°C 12°C 19°C 30°C 12°C 19°C 30°C 
F1    F21    S2    
F2    F22    S3    
F3    F23    S4    
F4    F24    S5    
F5    F25    S6    
F6    F26    S7    
F7    F27    S8    
F8    F28    S9    
F9    F29    S10    
F10    F30    S11    
F11    F31    C1    
F12    F32    C2    
F13    F33    C3    
F14    F34    C4    
F15    F35    C5    
F16    F36    C6    
F17    F37    Pb    
F18    F38    Pd    
F19    F39    Pp    
F20    S1    Pr    
 





3.2 Preliminary Pairwise Testing 
All 50 F- and S-strains were pairwise tested at room temperature against Pb and Pp.  
Seven strains showed strong inhibition (>75%) against Pb and 11 strains showed strong 
inhibition against Pp. The 33 psychrotolerant strains were tested against Pd and Pr at 12°C. 
Nine strains showed strong inhibition (>75%) against Pd and 8 strains showed strong 
inhibition against Pr (Fig 12; Table 2). The strains that performed best at room temperature 
were F1, F3, F14, F24, F31, F39, S2, S8, S9, and S11; the strains that performed best at 
12°C were F1, F3, F5, F38, S1, S2, S5, S8, S9, and S11. The strains F1, F3, S2, S8, and S9 
(Fig 13) showed at least partial inhibition against each P-strain, with the highest overall 
combined scores; these strains were used for all subsequent analyses. The nature of the 
inhibition of these strains based on preliminary pairwise testing could have been either 
resource or interference based, and either innate or induced. Regardless, these five strains 
presented the best potential in the current strain library for finding novel antifungals, or 
even known antifungals with previously uncharacterized action against Pd. 

















Figure 12. Observed pairwise inhibition between F1 and 
Pd (Right: top view; Left: reverse image of bottom view) 
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Figure 13. Morphology of selected isolate strains 
 
Table 2. Inhibition heatmap of preliminary pairwise testing of the strain library against P-
strains with Pb and Pp trials at room temperature and Pd and Pr trials at 12°C 
Strain 
Pairwise Inhibition Score* 
Strain 
Pairwise Inhibition Score* 
Pb Pd Pp Pr Pb Pd Pp Pr 
F1     F26     
F2     F27     
F3     F28     
F4     F29     
F5     F30     
F6     F31     
F7     F32     
F8     F33     
F9     F34     
F10     F35     
F11     F36     
F12     F37     
F13     F38     
F14     F39     
F15     S1     
F16     S2     
F17     S3     
F18     S4     
F19     S5     
F20     S6     
F21     S7     
F22     S8     
F23     S9     
F24     S10     
F25     S11     
*Inhibition Scale: No Data 0 1 2 3  
F1 F3 S2 S8 S9 
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3.3 Analysis of Crude Extracts 
After two weeks of growth on 250mL 
of 100% YMA media, the metabolites of the 
pure isolate strains (F1, F3, S2, S8, and S9; 
Fig 14), pure P-strains, pairwise 
inoculations of the isolate and P-strains, and 
an agar control were extracted and made up 
to 10mg/mL in methanol. The pairwise 
samples S2xPb, S2xPp, S9xPb, and S9xPp 
had to be regrown, and could only be grown 
for one week before extraction, resulting in 
a weaker yield, and a concentration of only 
1mg/mL for LC analysis. LC/MS/DAD was 
run on the pure strains P-strains, an agar control sample, and a methanol control (Appendix 
B, Fig B1-B2), as well as each pure and pairwise isolate strains (Appendix B, Fig B3-B7); 
the total ion chromatogram and full-range (190-400nm) UV chromatogram were obtained 
for comparison. By comparing the pure isolate and P-strain chromatograms, unique signals 
in the pairwise sample were noted (Fig 15). Table 3 summarizes the number of unique 















Figure 14. Crude extracts of selected 
strains. 
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Table 3. Number of unique signals induced by the pairwise culturing of isolate and P-




# Unique Signals Induced 
Pb Pd Pp Pr 
F1 3 3 6 2 
F3 0 1 0 2 
S2 2 2 0 0 
S8 0 0 0 2 
S9 0 0 0 0 
 
Due to the decreased growth time and metabolite concentration, the spectra of 
pairwise samples S2xPb, S2xPp, S9xPb, and S9xPp yielded low intensity signals, making 
accurate compound comparison difficult. Based on the number and intensity of unique 
signals in the F1 pairwise spectra, compounds were likely induced by the stress of co-
culturing (Appendix B, Fig B3). However, whether or not the induced compounds have 
antifungal activity, and whether the unique compounds were produced by the isolate or the 
P-strain cannot be determined based on this method. Isolate strains F3, S2, S8, and S9 show 
few or very low intensity signals unique to the pure isolate and P-strain spectra, meaning 
novel metabolites were likely not induced under the co-culturing circumstances (Appendix 
B, Fig B4-B7). The retention times and relative intensities of induced peaks were reported 







3.4 Assessing Bioactivity of Extracted Metabolites 
3.4.1 Isolate-Supplemented Media Testing: 
Each isolate-supplement media testing slowed the health and rate of growth of every 
P-strain in the first seven days compared to the control. However, after ten days of growth, 
the F3 and S8 supplemented media did not show any significant difference in coverage 
from the control for any of the P-strains. F1 and S2 supplemented media both inhibited Pd 
moderately, but neither had a significant effect on the other three P-strains. S9 
supplemented media showed moderate inhibition of both Pp and Pr, and complete 
inhibition of both Pb and Pd (Table 4). 
Table 4. Heatmap of P-strain plate coverage on isolate-supplemented media 
Isolate Supplement 
Coverage Score* 
Pb Pd Pp Pr 
F1     
F3     
S2     
S8     
S9     
C     
*Coverage Scale: 0 1 2 3  
 
  
 The lack of strong overall inhibition by strains F1, F3, S2, and S8 suggest that none 
of them have significant innate antifungal metabolite production that is active against 
Pseudogymnoascus fungi. This indicates that the inhibition observed in the preliminary 
trials may have been a result of resource-limited condition where the isolate strains out-
competed the P-strains, as opposed to true metabolite-based interference competition. 
However, this along with the LC/MS/DAD data suggests that in the case of F1, it is possible 
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that this type of interference is being induced in co-culture conditions. Nevertheless, S9 
appears to have significant innate activity, specifically towards Pb and Pd.  
It was determined that the compounds produced by S9 were able to prevent the 
growth of Pb and Pd for at least 8 weeks (at which point the media began to dehydrate and 
crack) when supplemented into the media. In the consecutive extractions and 
supplementations using S9 metabolites, all four P-strains were inhibited in the first round 
(R1). After extraction and re-supplementation (R2), S9 metabolites retained activity against 
Pb and Pd, but lost some activity against Pp and Pr. After the final extraction and 
supplementation (R3), activity was retained against Pb and Pd but completely lost in Pp 
and Pr (Table 5). LS/MS/DAD analysis of the initial extract and extracts from R1 and R2 
plates showed that the metabolite profile did not change from the initial extract to the R1 
extraction. However, the metabolite profile diminished after the R2 extraction in Pp and 
Pr, but not Pb and Pd (Appendix B, Fig B8-B12). 
Table 5. P-strain plate coverage on consecutive S9-supplemented media tests 
S9 Supplement 
Coverage Score* 
Pb Pd Pp Pr 
R1 S9     
R1 Control     
R2 S9     
R2 Control     
R3 S9     
R3 Control     
*Coverage Scale: 0 1 2 3  
 
The specific and ongoing inhibition of Pb and Pd, and limited inhibition of Pp and 
Pr was observed again. However, the chromatograms give evidence as to reason for the 
decreased activity against Pp and Pr; the metabolite profile after the extraction from the 
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second round of supplemented media tests revealed that the Pp and Pr media were missing 
a distinct peak that eluted at 17.7min. This peak was present in the controls for each round 
and in the Pb and Pd media, but appears to have been degraded by Pp and Pr. It should be 
noted, that S9, Pp, and Pr were all isolated from hibernacula-adjacent environments and 
have likely coevolved, allowing these P-strains to develop mechanisms to combat or reduce 
the effect of the S9 antifungal compounds. However, S9 evolved independently from Pb 
and Pd, therefore its antifungal defences may be more effective against these strains. 
Overall, this result suggests that the compound eluting out at 17.7min is not only very stable 
(able to be extracted out of media at least three times) but may be the compound responsible 
for the innate antifungal action of S9 and will be a focus moving forward. The retention 
times, relative intensities of induced peaks, and associated masses were reported in 
Appendix A, Table A4. Higher resolution mass spectrometry is required to gain meaningful 
information about the composition and structure of the unknown compounds.  
 
3.4.2 Disc Diffusion Assay: 
After ten days of growth, the P-strain fungi overtook the plates with only a few 
discs showing visible zones of inhibition (Table 6). Most observed zones of inhibition were 
minimal, with just 1mm of visible inhibition from the edge of the discs. The only moderate 
to distinct zones of inhibition were due to the crude S9 extracts against Pb and Pd and the 
sixth fraction (100% ACN) of S9 on Pd. The inhibition of Pb and Pd by the crude S9 
sample was expected due to the innate activity observed in the supplemented media tests. 
However, the moderate zone of inhibition around the 100% ACN disc supports the 
prediction that the bioactive metabolite is likely one that eluted out in the later stages of the 
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LC run (possibly 17.7min). The minimal results for the crude and fractionated samples of 
F1, F3, S2 and S8 could be due to the lack of innate antifungal activity (also observed in 
the supplemented media tests) and the extremely low concentration of metabolites each 
solvent after fractionation.  
 
Table 6. Zone of inhibition of P-strains on disc diffusion assays 
Fraction 
Zone of Inhibition Score* 
Fraction 
Zone of Inhibition Score* 
Pb Pd Pp Pr Pb Pd Pp Pr 
Crude F1     Crude S8     
F1 Fraction 1     S8 Fraction 1     
F1 Fraction 2     S8 Fraction 2     
F1 Fraction 3     S8 Fraction 3     
F1 Fraction 4     S8 Fraction 4     
F1 Fraction 5     S8 Fraction 5     
F1 Fraction 6     S8 Fraction 6     
Crude F3     Crude S9     
F3 Fraction 1     S9 Fraction 1     
F3 Fraction 2     S9 Fraction 2     
F3 Fraction 3     S9 Fraction 3     
F3 Fraction 4     S9 Fraction 4     
F3 Fraction 5     S9 Fraction 5     
F3 Fraction 6     S9 Fraction 6     
Crude S2     Control MeOH     
S2 Fraction 1     Control Fraction 1     
S2 Fraction 2     Control Fraction 2     
S2 Fraction 3     Control Fraction 3     
S2 Fraction 4     Control Fraction 4     
S2 Fraction 5     Control Fraction 5     
S2 Fraction 6     Control Fraction 6     






In summary, it was shown that microbes isolated from bats and their hibernacula 
environments can have potent antimicrobial activity against Pseudogymnoascus 
destructans and closely related species. While in-depth analysis was only performed on 
five strains, a library consisting of 56 microbes associated with the North American bat 
species, Eptesicus fuscus, has been created, with multiple candidates also showing some 
degree of antifungal activity. Of the five strains analyzed, three (F3, S2, and S8) appear to 
be able to effectively compete with Pd and other Pga species for limited resources, if not 
by any interference mechanism. One strain (F1) shows evidence of producing potentially 
antifungal metabolites by induction when under the stress of coculture conditions. The final 
strain (S9) shows potent and innate antifungal activity, with specificity toward unfamiliar 
fungi (such as the invasive Pd).  
The key strength of this investigation was the development of standardized 
processes to screen for and determine mode of inhibition. The extraction process applied 
was able to remove metabolites from spent media for analysis without degradation and 
while maintaining bioactivity. However, the investigation fell short of isolating and 
identifying pure bioactive compounds. The main reason for this was the limitation of time, 
the extremely low metabolite yields, and the rudimentary nature of the fractionation process 
used. At no point were pure compounds able to be separated, preventing analysis with IR 
and NMR, and the resolution of the mass spectrometer prevented any compositional or 
structural information from being determined.  
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5. Future Work 
To further this investigation, the methods of purification and elucidation must be 
developed. Rather than manually fractionating, one dimension of a 2D LC could be used 
to separate and collect fractions based on detected signals, as opposed to approximate 
gradient composition. This would separate the crude extract in a more refined way, leading 
to a simpler purification process for samples; this would allow for IR and NMR analysis 
on the samples for identification or, in the case of a novel compound, elucidation. Adapting 
the current LC/MS method for use on a high-resolution mass spectrometer would help to 
determine the exact mass of compounds, making it easier to determine chemical 
composition and structure based on fragmentation and allow for more targeted searches in 
natural products databases. Once purified, the degree of bioactivity, the presence of 
synergistic effects, and the mechanism of action can also be deduced.  
To increase the potential discovery of antifungal compounds, the remaining 
candidates from the microbial library should be screened to determine if any other strains 
show bioactivity past the preliminary co-culture. Furthermore, methods of inducing 
metabolites could be expanded beyond simple co-culturing; by altering nutritional 
availability, introducing an artificial scaffolding to mimic the surface of bat skin, and 
introducing stressors such as changes in salt content, pH, and moisture levels, a larger 
variety of compounds with potential activity may be induced. Acquiring and screening 
microbes derived from European bats and hibernacula may yield more anti-Pd compounds 
due to the coevolution of European bats and the Pd fungus. 
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Finally, the identity of the microbes in the strain library should be determined. Then, 
the genome can be used to determine the biosynthetic pathways of elucidated antifungals 
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7. Appendix A – Extended Tabular Data 
Table A1. Faure Lab bat information and initial isolated strain count 
Bat ID Sex Age Location Isolated on 
 
Bat ID Sex Age Location Isolated on 
YMA R2A  YMA R2A 
P58 M A Molesworth 5 2  P86 F A Molesworth 3 1 
P60 M A Molesworth 4 3  P87 F A Molesworth 3 3 
P61 M A Molesworth 2 1  P89 F A Molesworth 0 0 
P62 M A Molesworth 3 2  P90 F A Molesworth 2 1 
P63 M A Molesworth 3 5  P91 F A Molesworth 3 2 
P64 M A Molesworth 2 3  P92 F A Molesworth 1 3 
P65 M A Molesworth 3 3  P94 F A Molesworth 2 5 
P66 F A Molesworth 2 2  P95 F A Molesworth 3 2 
P67 F A Molesworth 2 2  W181 M A Molesworth 2 5 
P68 F A Molesworth 3 1  R113 F J Captivity 2 3 
P69 F A Molesworth 2 2  R115 M J Captivity 2 2 
P70 F A Molesworth 2 2  R116 F J Captivity 4 1 
P71 F A Molesworth 2 1  R119 M J Captivity 3 2 
P72 F A Molesworth 2 1  R234 M J Captivity 2 1 
P73 F A Molesworth 2 2  R235 M J Captivity 3 2 
P75 F A Molesworth 2 3  R237 M J Captivity 2 3 
P79 F A Molesworth 0 3  R240 F J Captivity 2 3 
P80 F A Molesworth 2 1  R250 M J Captivity 2 2 
P81 F A Molesworth 1 1  R265 F J Captivity 2 2 











Table A2. Final strain library and morphology 
Strain Source Identity Morphology 
F1 Faure Lab Unknown (Fungus) White-yellow-green, raised  
F2 Faure Lab Unknown (Fungus) Colourless-grey, long fibres  
F3 Faure Lab Unknown (Fungus) Purple-brown, solid, shiny, flat  
F4 Faure Lab Unknown (Bacteria) Bright yellow, opaque, matte 
F5 Faure Lab Unknown (Bacteria) Yellow-brown, translucent, waxy 
F6 Faure Lab Unknown (Fungus) Grey/green, flat 
F7 Faure Lab Unknown (Fungus) Green, soft, flat 
F8 Faure Lab Unknown (Fungus) Colourless, long fibres 
F9 Faure Lab Unknown (Fungus) Green with dark green spheres 
F10 Faure Lab Unknown (Fungus) Colourless, short fibres, lawn 
F11 Faure Lab Unknown (Fungus) Colourless with dark green spheres 
F12 Faure Lab Unknown (Fungus) Grey, flat, lawn 
F13 Faure Lab Unknown (Bacteria) White, opaque, shiny 
F14 Faure Lab Unknown (Fungus) Brown, flat, lawn 
F15 Faure Lab Unknown (Bacteria) White, opaque, matte, flat 
F16 Faure Lab Unknown (Bacteria) White, translucent, shiny 
F17 Faure Lab Unknown (Fungus) Green with white edge, flat 
F18 Faure Lab Unknown (Bacteria) Pale yellow, opaque, matte 
F19 Faure Lab Unknown (Bacteria) White, opaque, matte 
F20 Faure Lab Unknown (Bacteria) White, opaque, shiny 
F21 Faure Lab Unknown (Bacteria) Purple-brown, solid, shiny, flat 
F22 Faure Lab Unknown (Fungus) Green with white edge, raised 
F23 Faure Lab Unknown (Bacteria) Bright yellow, opaque, shiny 
F24 Faure Lab Unknown (Fungus) White-yellow-green, raised lawn 
F25 Faure Lab Unknown (Bacteria) Dark yellow, opaque, matte 
F26 Faure Lab Unknown (Bacteria) Colorless, pinform, circular 
F27 Faure Lab Unknown (Bacteria) Pale yellow, opaque, matte 
F28 Faure Lab Unknown (Bacteria) Pale yellow, opaque, shiny 
F29 Faure Lab Unknown (Bacteria) Pale yellow, translucent, pinform 
F30 Faure Lab Unknown (Fungus) Yellow-green, flat, lawn 
F31 Faure Lab Unknown (Fungus) White-yellow-green, soft 
F32 Faure Lab Unknown (Bacteria) Bright pink, opaque, matte 
F33 Faure Lab Unknown (Fungus) White-yellow-green, flat 
F34 Faure Lab Unknown (Bacteria) Bright yellow, opaque, matte 
F35 Faure Lab Unknown (Fungus) Grey/green, flat, lawn 
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F36 Faure Lab Unknown (Fungus) White, raised lawn 
F37 Faure Lab Unknown (Fungus) Grey, flat, lawn 
F38 Faure Lab Unknown (Fungus) White-yellow, flat, lawn 
F39 Faure Lab Unknown (Bacteria) Yellow-brown, translucent, waxy 
S1 Smith Lab Bacillus sp. 39 White, translucent, matte, irregular 
S2 Smith Lab Trichoderma atroviride39 White-yellow-green, raised lawn 
S3 Smith Lab Lecanicillium sp. 39 White, raised lawn 
S4 Smith Lab Pantoea ananatis39 Pale yellow, translucent, matte 
S5 Smith Lab Penicillium sp. 39 Green-grey, flat, lawn 
S6 Smith Lab Pseudomonas sp.40 Off-white, translucent, waxy, 
matte 
S7 Smith Lab Unknown (Fungus) Brown/purple, flat, lawn 
S8 Smith Lab Sphingobium sp. 39 White-pink, raised irregular 
S9 Smith Lab Penicillium canescens39 White-green-blue, raised lawn 
S10 Smith Lab Paecilomyces inflatus 39 White-pink, solid, irregular 
S11 Smith Lab Trichoderma harzianum 39 White-yellow-green, soft 
C1 Contaminant Unknown (Fungus) Colourless, long fibres 
C2 Contaminant Unknown (Bacteria) White, opaque, shiny 
C3 Contaminant Unknown (Bacteria) Bright yellow, opaque, shiny 
C4 Contaminant Unknown (Bacteria) White, translucent, matte 
C5 Contaminant Unknown (Bacteria) Yellow-brown, translucent, waxy 
C6 Contaminant Unknown (Bacteria) White, opaque, matte, irregular 
Pb ATCC 
(28807) 
Pseudogymnoascus bhatti Yellow-brown, raised, solid 
Pd Smith Lab Pseudogymnoascus 
destructans39 
White-grey, circular, raised 
Pp Smith Lab Pseudogymnoascus pannorum39 White-grey, flat, lawn 
Pr Smith Lab Pseudogymnoascus roseus39 White-pink, flat, lawn 
  
Table A3. Retention times and relative intensities of induced peaks from UV 
chromatograms 
Pairwise Strains Retention Time (min) Relative Intensity (%) 
F1xPb 14.5 100 
F1xPb 16.5 11.8 
F1xPb 18.0 89.0 
F1xPd 3.7 22.2 
F1xPd 10.1 12.8 
F1xPd 13.5 26.5 
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F1xPp 11.9 5.8 
F1xPp 12.2 17.9 
F1xPp 13.5 16.4 
F1xPp 14.5 75.8 
F1xPp 16.5 10.6 
F1xPp 18.0 100 
F1xPr 26.0 7.5 
F1xPr 26.5 12.8 
F3xPd 10.5 11.8 
F3xPr 26.0 14.3 
F3xPr 26.6 11.6 
S2xPb 8.3 14.3 
S2xPb 11.4 4.9 
S2xPd 7.5 7.0 
S2xPd 24.3 10.6 
S8xPr 26.1 13.9 
S8xPr 26.6 10.3 
 
Table A4. Retention times, relative intensities, and associated masses of compounds from 
total ion chromatogram of crude S9 extract  
Retention Time  
(min) 
Relative Intensity  
(%) Mass List (m/z) * 
3.1 7.0 206.0, 234.0, 247.0 262.0, 469.0 
5.4 26.5 206.0, 234.0, 261.0, 278.0, 289.0 
6.0 7.7 216.0, 263.0, 370.0, 422.0, 454.0  
9.2 8.3 168.0, 185.1, 213.0, 256.0, 526.1 
9.7 47.9 168.1, 185.1, 213.0, 256.0, 508.1 
10.5 33.5 165.0, 199.9, 214.9, 224.0, 375.0 
10.9 19.4 156.1, 182.0, 185.0, 197.0, 278.0 
11.6 38.8 168.0, 185.1, 213.0, 258.1, 510.1 
12.1 32.9 148.0, 202.0, 265.1, 584.2, 606.2 
15.5 35.5 441.0, 438.0, 611.0, 629.1, 1235.1 
17.7 100 185.1, 197.1, 213.1, 225.1, 569.1 
*Base peak for each compound is bolded  
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8. Appendix B – Spectral Data 
 






































































Figure B3. Total ion chromatograms (black) and full range UV chromatograms (blue) of 










F1 x Pd 
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Figure B4. Total ion chromatograms (black) and full range UV chromatograms (blue) of 









F3 x Pd 
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Figure B5. Total ion chromatograms (black) and full range UV chromatograms (blue) of 










S2 x Pd 
 
 




S2 x Pr 
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Figure B6. Total ion chromatograms (black) and full range UV chromatograms (blue) of 









S8 x Pd 
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Figure B7. Total ion chromatograms (black) and full range UV chromatograms (blue) of 











S9 x Pd 
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Figure B8. Total ion chromatograms (black) and full range UV chromatograms (blue) of 

































Figure B9. Total ion chromatograms (black) and full range UV chromatograms (blue) of 




































Figure B10. Total ion chromatograms (black) and full range UV chromatograms (blue) 




































Figure B11. Total ion chromatograms (black) and full range UV chromatograms (blue) 



































Figure B12. Total ion chromatograms (black) and full range UV chromatograms (blue) 
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